Meeting
2021 ASCO Annual Meeting
A phase II clinical trial of talazoparib monotherapy for PALB2 mutation‑associated advanced breast cancer.
Authors
Joshua James Gruber
Stanford University, Palo Alto, CA
Joshua James Gruber , Wyatt Gross , Alex McMillan , James M. Ford , Melinda L. Telli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
pending
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS1109)
DOI
10.1200/JCO.2021.39.15_suppl.TPS1109
Abstract #
TPS1109
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
First Author: June Evelyn Jeon
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2022 ASCO Annual Meeting
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene–mutated, metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Neeraj Agarwal
Poster
2022 ASCO Genitourinary Cancers Symposium
Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Neeraj Agarwal